Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response

Hauck, 2008, Enhancing the toxicity of cancer chemotherapeutics with gold nanorod hyperthermia, Adv. Mater., 20, 3832, 10.1002/adma.200800921

Kintzel, 1995, Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function, Cancer Treat. Rev., 21, 33, 10.1016/0305-7372(95)90010-1

Allen, 2013, Liposomal drug delivery systems: from concept to clinical applications, Adv. Drug Deliv. Rev., 65, 36, 10.1016/j.addr.2012.09.037

Barenholz, 2012, Doxil®- the first FDA-approved Nano-drug: lessons learned, J. Control. Release, 160, 117, 10.1016/j.jconrel.2012.03.020

Petre, 2007, Liposomal daunorubicin as treatment for Kaposi's sarcoma, Int. J. Nanomedicine, 2, 277

Batist, 2001, Reduced cardiotoxicity and preserved antitumor efficacy pf liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer, J. Clin. Oncol., 19, 1444, 10.1200/JCO.2001.19.5.1444

Seynhaeve, 2013, Intact doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo cell imaging, J. Control. Release, 172, 330, 10.1016/j.jconrel.2013.08.034

Yatvin, 1978, Design of liposomes for enhanced local release of drugs by hyperthermia, Science, 202, 1290, 10.1126/science.364652

Yatvin, 1981, Selective delivery of liposome-asociated cis-dichlorodiammine platinum (II) by heat and its influence on tumor drug uptake and growth, Cancer Res., 41, 1602

Kong, 1999, Hyperthermia and liposomes, Int. J. Hyperth., 15, 345, 10.1080/026567399285558

Needham, 2013, Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE–PEG2000) on the thermal transition and release of doxorubicin, Faraday Discuss., 161, 515, 10.1039/C2FD20111A

http://clinicaltrials.gov/ct2/results?term=thermodox.

Chiu, 2005, Encapsulatuon of doxorubicin into thermosensitive liposomes via complexation with transition metal manganese, J. Control. Release, 104, 271, 10.1016/j.jconrel.2005.02.009

Banno, 2010, The functional roles of poly-(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo, J. Pharm. Sci., 99, 2295, 10.1002/jps.21988

Chen, 2013, A thermoresponsive bubble-generating liposomal system for triggering localized extracellular drug delivery, ACS Nano, 7, 438, 10.1021/nn304474j

Manzoor, 2012, Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors, Cancer Res., 72, 5566, 10.1158/0008-5472.CAN-12-1683

Mills, 2004, The materials enginnering of temperature-sensitive liposomes, Methods Enzymol., 387, 82, 10.1016/S0076-6879(04)87006-X

Casazza, 1980, Effects of modifictions in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin, 403

Wiernik, 1992, Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia, Blood, 79, 313, 10.1182/blood.V79.2.313.313

Berman, 1991, Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia, Blood, 77, 1666, 10.1182/blood.V77.8.1666.1666

Vogler, 1992, A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a southeastern cancer study group, J. Clin. Oncol., 10, 1103, 10.1200/JCO.1992.10.7.1103

Ma, 2009, Development of idarubicin and doxorubicn solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia, J. Biomed. Nanotechnol., 5, 151, 10.1166/jbn.2009.1021

Ames, 1992, Selected pharmacologic charachteristics of idarubicin and idarubicinol, Leukemia, 6, 70

Roovers, 1999, Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines, Leuk. Res., 23, 539, 10.1016/S0145-2126(99)00041-7

Gubernator, 2010, The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo, J. Control. Release, 146, 68, 10.1016/j.jconrel.2010.05.021

Dos Santos, 2002, Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes, Biochim. Biophys. Acta, 1561, 188, 10.1016/S0005-2736(02)00345-0

Gupta, 1988, Investigation of the stability of doxorubicin hydrochloride using factorial design, Drug Dev. Ind. Pharm., 14, 1657, 10.3109/03639048809151980

Vichai, 2006, Sulforhodamine B colorimetric assay for cytotoxicity screening, Nat. Protoc., 3, 1112, 10.1038/nprot.2006.179

Hossann, 2010, Size of thermosensitive liposomes influences content release, J. Control. Release, 147, 436, 10.1016/j.jconrel.2010.08.013

Nagayasu, 1999, The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs, Adv. Drug Deliv. Rev., 40, 75, 10.1016/S0169-409X(99)00041-1

Kirby, 1980, Effect of cholesterol content of smallunilamellar liposomes on their stability in vivo and iv vitro, Biochem. J., 186, 591, 10.1042/bj1860591

Coderch, 2000, Influence of cholesterol on liposome fluidity by EPR relationship with percutaneous absorption, J. Control. Release, 68, 85, 10.1016/S0168-3659(00)00240-6

Gallois, 1998, Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles: circular dichroismstudy, Biochim. Biophys. Acta, 1370, 31, 10.1016/S0005-2736(97)00241-1

Tieleman, 2002, Molecular dynamics simulation of the evolution of hydrophobic defects in one monolayer if a phosphatidylcholine bilayer: relevance for membrane fusion mechanisms, Biophys. J., 83, 1501, 10.1016/S0006-3495(02)73920-9

Needham, 2001, The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors, Adv. Drug Deliv. Rev., 53, 285, 10.1016/S0169-409X(01)00233-2

Landon, 2011, Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer, Open Nanomed. J., 3, 38, 10.2174/1875933501103010038

Cui, 2011, Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage, J. Pharm. Sci., 100, 2835, 10.1002/jps.22496